# Revalia Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/revalia-bio

- Industry: Biotechnology
- Headquarters: New Haven, US
- Website: www.revaliabio.com
- Total disclosed funding: $12M
- Latest round: Seed (Oct 25, 2024)
- Investors on record: 2

## About

Revalia Bio, Inc., based in New Haven, US, specializes in biotechnological solutions, focusing on drug development through innovative human data trials utilizing organ-based insights to enhance therapeutic evaluations.Revalia Bio, Inc. operates a Human Data Trials platform that streamlines drug development processes. Founded in New Haven, USA, the company recently raised USD 14.5 mn in Seed funding on September 4, 2025, co-led by America's Frontier Fund and Sierra Ventures, to enhance its research capabilities. The company has not undergone any pivots or changes in business operations since its inception.Revalia Bio’s primary offering is its Human Data Trials platform, which facilitates drug development by utilizing high-fidelity, organ-based human data obtained from donated, perfused human organs. This innovative approach enables biopharma teams to gain early insights into the safety, efficacy, and mechanisms of action of therapeutic candidates prior to the initiation of clinical trials, addressing significant gaps in traditional drug development methodologies that often rely heavily on animal models. The company targets a variety of stakeholders in the healthcare ecosystem, including physician-scientists, health systems, and biotechnology firms, all of whom benefit from the publication-grade insights generated through Revalia’s platform. Revalia's services are designed to reduce trial risks and enhance the translational relevance of research findings, with a particular focus on markets in North America and Europe where the integration of organ donation into research is actively supported.Revalia Bio’s revenue model is built on partnerships and collaborations with biopharma companies, health systems, and research institutions, providing them access to its unique Human Data Trials. The transactions typically involve subscription agreements or collaborative research contracts, whereby clients engage Revalia to facilitate studies using human tissues and data. This structure allows clients to leverage Revalia’s infrastructure and expertise to accelerate their own drug discovery processes while sharing in the resultant insights and data. Flagship services include the comprehensive analysis of therapeutic candidates through early human insights that inform trial designs, biomarkers, and dosing strategies. By transforming donated organs into a resource for scientific exploration, Revalia not only supports the advancement of medicine but also strengthens the financial viability of its offerings through strategic engagement with top-tier pharmaceutical companies.In September 2025, Revalia Bio, Inc. raised USD 14.5 mn in Seed funding to expand its human organ research platform, enabling accurate evaluations of drug candidates. The company aims to enhance its product offerings and explore new markets, particularly in Europe and North America, where its innovative approach to drug development can be effectively integrated. The funding will support operational growth and the development of new products that leverage organ-based insights for drug evaluation.

## Funding rounds

- Seed, Oct 25, 2024, $12M — Sierra Ventures, America's Frontier Fund

## Investors

- Sierra Ventures (https://capitalatlas.ai/funds/sierra-ventures) — Seed
- America's Frontier Fund (https://capitalatlas.ai/funds/america-s-frontier-fund) — Seed